Medshine Discovery Inc. has prepared octahydropyrazinodiazanaphthyridine dione compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has synthesized PROTAC compounds comprising an E3 ubiquitin ligase binding moiety coupled to IRAK-4-targeting moiety through a linker.
Medshine Discovery Inc. has divulged halogen-substituted pyridazinone compounds acting as short transient receptor potential channel 5 (TRPC5) antagonists reported to be useful for the treatment of hypertensive nephropathy.
Medshine Discovery Inc. has identified acrylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of cancer.
Research at Medshine Discovery Inc. has led to the development of imidazocyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes.
Medshine Discovery Inc. has divulged nuclear receptor ROR-γ (RORC) agonists or RORC inverse agonists reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has synthesized macrocyclic compounds acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infections.
Medshine Discovery Inc. has divulged amide compounds acting as epidermal growth factor receptor (EGFR) mutant inhibitors reported to be useful for the treatment of cancer.
